Develops immune-based cancer drug candidates for patients whose cancers resist immunotherapy.
10-K for FY2025, filed Mar 31, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
10-Q for Q3 FY2026, filed Nov 13, 2026
−$6.4MView ↗
Pipeline focus
The older report described chemotherapy and light-activated therapy candidates; the latest focuses on immune-based treatments, including an innate immune agonist, a VISTA-inhibiting antibody and immune-modulating antibody-drug conjugates.
10-K for FY2022, filed Sep 27, 2022 10-K for FY2025, filed Mar 31, 2026Our two lead candidates are VAL-083, a novel, validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as…View ↗
Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the body’s immune…View ↗
In addition to our IFx technology platform, in June 2025 we acquired the rights to TBS-2025, a novel VISTA-inhibiting monoclonal antibody…View ↗
In addition to our IFx and TBS-2025, we are leveraging our Delta Opioid Receptor (DOR) technology to develop first-in-class bi-functional…View ↗
Loading...